title: Catch-up growth in severe juvenile hypothyroidism: treatment with a GnRH analog.
abstract: Anecdotal reports suggest that the addition of a gonadotropin releasing hormone (GnRH) analog (GnRHa) in addition to L-thyroxine (LT4) replacement may increase adult stature in children with severe longstanding hypothyroidism by prolonging the pubertal growth period. This retrospective chart review compares the height outcome and body mass index in 33 children (21 treated with LT4 alone and 12 treated with LT4 + GnRHa) with severe longstanding hypothyroidism and bone age delay. Seventeen controls and six GnRHa-treated patients were followed to adult height (BA >14 yr [F]/16 yr [M] and/or growth velocity < 2 cm/yr). At diagnosis, GnRHa-treated patients were 1) older and shorter for chronological age, and 2) more advanced in puberty and bone age. Despite these differences, at adult height, both groups had similar improvements in height Z scores, similar height deficits, and comparable adult heights. Changes in BMI Z score were similar for both groups. Our study suggests that the addition of GnRHa to LT4 may improve interval growth without imposing a risk of obesity in children with longstanding severe hypothyroidism.
authors.affiliation: Pediatric Endocrinology and Diabetes, Stanford Medical Center, Stanford, CA 94305-5208, USA.
authors.forename: Louisa
authors.initials: L
authors.lastname: Teng
authors.forename: Helen
authors.initials: H
authors.lastname: Bui
authors.forename: Laura
authors.initials: L
authors.lastname: Bachrach
authors.forename: Peter
authors.initials: P
authors.lastname: Lee
authors.forename: Nancy
authors.initials: N
authors.lastname: Gagné
authors.forename: Cheri
authors.initials: C
authors.lastname: Deal
authors.forename: Darrell M
authors.initials: DM
authors.lastname: Wilson
mesh_terms: D000293:Adolescent; D000328:Adult; D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D015992:Body Mass Index; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006128:Growth / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007037:Hypothyroidism / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D018579:Patient Selection; D011627:Puberty / Q000187:drug effects; D012189:Retrospective Studies; D013974:Thyroxine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects / Q000502:physiology
chemical_list: D007987:Gonadotropin-Releasing Hormone; C083781:LHRH, Ala(6)-Gly(10)-ethylamide-; D013974:Thyroxine